Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expiration dates for Trulicity, Mounjaro, and other blockbuster medicines mean every Eli Lilly disclosure can shift expectations for future cash flow. If you have ever searched for Eli Lilly SEC filings explained simply, you know how dense a pharmaceutical 10-K can be. Stock Titan’s AI reads each document the instant it posts to EDGAR and serves a concise summary that highlights clinical-trial outcomes, FDA correspondence, and global pricing risks—turning hundreds of pages into a five-minute briefing.
Need details from the latest Eli Lilly quarterly earnings report 10-Q filing or a quick take on cash used for R&D? Our platform flags segment revenue, pipeline spend, and patent-life tables while linking directly to the full text. The annual report is here as the Eli Lilly annual report 10-K simplified; Form 8-K alerts keep you current with trial readouts and collaborations—see Eli Lilly 8-K material events explained. When proxy season arrives, the Eli Lilly proxy statement executive compensation section breaks down option awards, pay-for-performance metrics, and governance votes, all with clear AI commentary.
Monitoring insider sentiment? Track Eli Lilly insider trading Form 4 transactions and receive Eli Lilly Form 4 insider transactions real-time notifications. Our dashboards group every Eli Lilly executive stock transactions Form 4 with trend charts so you can spot buying or selling patterns before the market reacts. Use the built-in tools for Eli Lilly earnings report filing analysis or simply browse by form if you prefer traditional reading. Whether you’re comparing quarter-over-quarter margins or understanding Eli Lilly SEC documents with AI, this page delivers every filing, every update, in a workflow that saves hours and sharpens your investment decisions.
Eli Lilly and Company reported an initial insider ownership filing for a director. The reporting person is identified as a director of Eli Lilly and holds 2,000 shares of the company’s common stock in direct ownership. This type of filing gives investors visibility into how many shares a company insider beneficially owns at the time they become a reporting person.
The document is signed under a power of attorney authorization, indicating that the signature was provided on the director’s behalf. There are no derivative securities, such as options or warrants, listed as beneficially owned in this filing.
Eli Lilly & Co. (LLY) director Lilly Endowment Inc. reported open-market sales of Eli Lilly common stock on 11/25/2025. The Endowment sold 5,043 shares at a weighted average price of $1,108.71, 9,249 shares at a weighted average price of $1,109.449, and 1,340 shares at a weighted average price of $1,110.527, for a total of 15,632 shares sold.
After these transactions, Lilly Endowment Inc. beneficially owned 92,196,978 shares of Eli Lilly common stock, held directly. The prices reported reflect multiple trades within narrow ranges for each block of shares. This filing is identified as the second of two Forms 4 filed by the reporting person on the same date, covering transactions numbered 31 through 33 of 33 total transactions.
Lilly Endowment Inc., a director-level reporting person of Eli Lilly & Co (LLY), reported a series of open-market sales of Eli Lilly common stock on 11/25/2025. The Form 4 lists 30 separate sale transactions, each coded as an "S" for sale, with weighted average prices including
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co (LLY), reported multiple sales of Eli Lilly common stock on 11/24/2025. The largest block shown was 120,016 shares sold at a weighted average price of
After these transactions, Lilly Endowment directly beneficially owned 92,359,671 shares of Eli Lilly common stock. The prices reported are weighted averages for multiple trades within narrow price ranges, and the reporting person has indicated a willingness to provide detailed trade breakdowns upon request.
Eli Lilly & Co. (LLY) reported a series of share sales by a 10% owner on 11/21/2025. The Form 4 shows Lilly Endowment Inc., filing as a single reporting person, disposing of multiple blocks of common stock in open-market transactions coded "S" for sale.
The reported trades cover numerous small tranches, such as 9,871 shares at a weighted average price of $1,050.272 and 23,916 shares at $1,059.658, with additional sales at prices generally between about $1,050 and $1,066.15. After these transactions, the reporting person beneficially owned 92,501,978 shares of Eli Lilly common stock, held directly.
Lilly Endowment Inc. filed a Form 144 notice covering a proposed sale of 305,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets, with an aggregate market value of $323,208,500. The notice lists 945,383,757 Eli Lilly shares outstanding. The Endowment’s shares being sold trace back to a large historical gift; it reports acquiring 38,400,000 Eli Lilly common shares via a gift from the J.K. Lilly Sr. Trust dated in the 1930s–1940s.
The filing also details extensive recent selling activity by Lilly Endowment. Over the past three months, it executed multiple Eli Lilly stock sales on the NYSE and NASDAQ, including transactions such as 351,015 shares on 10/01/2025 for gross proceeds of $284,653,451.48 and 305,000 shares on 11/12/2025 for $308,411,211.50. Individual daily trades during this period often exceeded 100,000 shares, with gross proceeds frequently above $80 million per day.
Eli Lilly and Company reported that its Board of Directors has elected Carolyn R. Bertozzi, Ph.D. as a new director, effective December 8, 2025. She is 59 and holds key academic roles at Stanford University, including Professor of Chemistry, Chemical & Systems Biology, and Radiology, and serves as an Investigator of the Howard Hughes Medical Institute.
Dr. Bertozzi will join Lilly’s Science and Technology Committee and the Ethics and Compliance Committee, bringing additional scientific and governance expertise. The Board has determined that she is independent under New York Stock Exchange standards and the company’s own guidelines. She will stand for election by shareholders at the annual meeting in May 2026 and will receive compensation under Lilly’s standard director compensation program.
Lilly Endowment Inc., a director of Eli Lilly & Co. (LLY), reported open-market sales of a total of 37,148 shares of common stock on 11/20/2025. The sales were executed in multiple tranches at weighted average prices ranging from $1,050.364 to $1,055.391 per share, with underlying trade prices spanning from $1,050.00 to $1,055.59, as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owns 92,607,304 shares of Eli Lilly common stock, held directly.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly and Company (LLY), reported multiple sales of Eli Lilly common stock on 11/19/2025. The transactions were open-market sales at weighted average prices between about $1,050 and $1,055 per share, executed in several blocks including 96,516 shares and 28,768 shares. After these sales, the reporting person beneficially owned 92,644,452 shares of Eli Lilly common stock, held directly. The prices disclosed are weighted averages for trades within narrow price ranges, and the reporting person notes that detailed trade information is available upon request.
Eli Lilly & Co. reported insider selling by a director on Form 4. On 11/18/2025, the reporting person executed a series of open-market sales of Eli Lilly common stock, coded "S" for sale. Across ten tranches, the director sold a total of 60,213 shares at weighted average prices ranging from about $1,030 to $1,040 per share, with each tranche reported alongside a specific weighted average price and price range.
Following these transactions, the reporting person directly beneficially owned 92,811,978 shares of Eli Lilly common stock. The filing notes that detailed breakouts of the individual trade prices within each weighted range are available upon request. The form is signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
What is the market cap of Lilly Eli & Co (LLY)?
